ENG/中
老虎證券
行情
交易
收费
优惠与活动
帮助
TigerAI
专栏
关于
登入
立即註冊
Toggle
澳股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
CSL LIMITED
138.500
+3.880
2.88%
成交量：
415.86萬
成交額：
6.37億
市值：
671.93億
市盈率：
34.13
高：
138.800
開：
135.990
低：
134.900
收：
134.620
52周最高：
269.118
52周最低：
133.350
股本：
4.85億
流通股本：
4.84億
量比：
3.47
換手率：
0.86%
股息：
4.15
股息率：
2.99%
每股收益(TTM):
4.058
每股收益(LYR):
8.762
淨資產收益率：
6.66%
總資產收益率：
6.58%
市淨率：
2.54
市盈率(LYR):
15.81
資料載入中...
總覽
公司
新聞資訊
公告
CSL 表示出血性疾病基因療法全球缺貨
路透中文
·
03/18
CSL有限公司正與監管機構協作制定策略 確保Hemgenix持續穩定供應
美股速递
·
03/17
CSL Seqirus將攜手長期合作伙伴Sinergium Biotech 供應差異化流感疫苗組合
美股速递
·
03/10
世衞組織若宣佈流感大流行 CSL旗下Seqirus將為加拿大提供佐劑化細胞培養疫苗
美股速递
·
03/05
禮來加入IL‑6競爭，從CSL獲得clazakizumab部分權益
Minhua笔记
·
02/18
1億美元首付款！禮來引進一款IL-6單抗
Medaverse
·
02/18
BUZZ-澳大利亞 CSL 公司與禮來公司簽署許可協議後恢復元氣
路透中文
·
02/18
更正-CSL 與禮來簽署克拉唑珠單抗許可協議
路透中文
·
02/18
CSL有限公司簽署獨家許可協議 獲Clazakizumab開發及商業化特定權利
美股速递
·
02/18
全球市場-美國就業數據好於預期，股市和美元跳漲；人工智能隱憂未消
路透中文
·
02/11
全球市場-對人工智能的擔憂加劇，股市暫停喘息；日圓大幅走高
路透中文
·
02/11
全球市場-股市喘息，日圓飆升
路透中文
·
02/11
異動解讀 | 鐵劑仿製藥競爭持續施壓，CSL LIMITED盤中大跌9.15%
异动解读
·
02/11
CSL有限公司：CSL Vifor業績將因鐵劑產品仿製藥競爭持續承壓
美股速递
·
02/11
CSL有限公司：免疫球蛋白、白蛋白及新品上市將驅動CSL Behring下半年業績增長
美股速递
·
02/11
Memo Therapeutics將利用Dropzylla平台開發重組多克隆抗體 實現抗體庫克隆與表達
美股速递
·
02/09
Memo Therapeutics Ag與CSL達成合作與期權協議 共同開發重組多克隆IgG技術
美股速递
·
02/09
焦點-美國衞生部長肯尼迪的言論成為現實，疫苗生產商倍感寒意
路透中文
·
01/22
異動解讀 | CSL LIMITED盤中大漲5.27%，子公司簽署重要備忘錄
异动解读
·
2025/10/30
CSL LIMITED - CSL Seqirus與疫苗工業公司與衞生部簽署重要諒解備忘錄
美股速递
·
2025/10/30
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CSL.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":138.5,"timestamp":1773983520000,"preClose":134.62,"halted":0,"volume":4158551,"delay":0,"changeRate":0.02882186896449261,"nameEN":"CSL LIMITED","floatShares":483950454,"shares":485151394,"eps":4.058440783868219,"marketStatus":"休市中","change":3.88,"latestTime":"03-20 16:12:00 AEDT","open":135.99,"high":138.8,"low":134.9,"amount":636891688,"amplitude":0.02897,"askPrice":138.6,"askSize":200,"bidPrice":138.1,"bidSize":210,"shortable":3,"etf":0,"ttmEps":4.058440783868219,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1774220400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":134.62,"dividendRate":0.029914,"openAndCloseTimeList":[[1773961200000,1773982800000]],"volumeRatio":3.4717679477714842,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":134.62,"auctionPrice":138.49,"auctionVolume":2223596,"auction":3,"marketStatus":"盘后竞价","timestamp":1773983424685}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":483950454,"roa":"6.58%","roe":"6.66%","lyrEps":8.761714,"volumeRatio":3.4717679477714842,"shares":485151394,"dividePrice":4.146549,"high":138.8,"amplitude":0.02897,"preClose":134.62,"low":134.9,"week52Low":133.35,"pbRate":"2.54","psRate":"3.07","week52High":269.118,"institutionHeld":0,"latestPrice":138.5,"committee":0.02439,"eps":4.058440783868219,"divideRate":0.029939,"volume":4158551,"delay":0,"ttmEps":4.058440783868219,"open":135.99,"prevYearClose":170.408,"prevWeekClose":141.03,"prevMonthClose":144.854,"prevQuarterClose":170.408,"fiveDayClose":141.03,"twentyDayClose":151.279,"sixtyDayClose":174.02,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":4,"dividendGrowthRate":0.11620984529927163,"fiveYearAvgDividendRate":0.013228653048611719},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"},{"date":"2025-08-19","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755561600000,"name":null,"time":"","dateTimestamp":1755525600000,"actualEps":null},{"date":"2025-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2025-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-09","payableDate":"2025-03-11","currency":"USD","dateTimestamp":1741525200000,"payDate":"2025-04-09"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620471351","title":"CSL 表示出血性疾病基因療法全球缺貨","url":"https://stock-news.laohu8.com/highlight/detail?id=2620471351","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620471351?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 00:37","pubTimestamp":1773765430,"startTime":"0","endTime":"0","summary":"路透3月17日 - 澳大利亚CSLCSL.AX公司表示，其出血性疾病基因疗法Hemgenix面临暂时性全球缺货，这将推迟该药物在已上市国家的部分患者的治疗。医生们认为，高昂的价格、物流问题和潜在的治疗进展前景阻碍了血友病基因疗法的采用。CSL表示，推迟治疗可能会影响到一些符合条件的患者，这些患者原本计划在已上市的国家接受一次性治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL4T4051K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0122379950.USD","LU0306807586.USD","LU0985481810.HKD","IE00B19Z3B42.SGD","LU1066051498.USD","SG9999011175.SGD","LU1066053197.SGD","SG9999013999.USD","IE00BLSP4239.USD","LU1023059063.AUD","BK4568","LU0321505439.SGD","IE00B19Z3581.USD","BK4592","IE0002270589.USD","IE00BLSP4452.SGD","SG9999002224.SGD","SGXZ57979304.SGD","BK4007","BK7501","SG9999003800.SGD","LU0868494617.USD","LU0170899867.USD","CSL.AU","IE00BBT3K403.USD","BK4585","LU1057294990.SGD","LU1894683264.USD","LU0289739699.SGD","LU1883839398.USD","LU0225284248.USD","LU0456855351.SGD","SG9999001176.SGD","LU0321505868.SGD","LU1894683348.USD","SG9999002232.USD","BK7508","BK4581","BK4533","SG9999001176.USD","IE000M9KFDE8.USD","BK7067","LU0058720904.USD","LU0225771236.USD","BK4588","BK4599","BK7511","BK4534","LU0306806265.USD","LU0234572021.USD"],"gpt_icon":0},{"id":"1128210509","title":"CSL有限公司正與監管機構協作制定策略 確保Hemgenix持續穩定供應","url":"https://stock-news.laohu8.com/highlight/detail?id=1128210509","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128210509?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 23:47","pubTimestamp":1773762439,"startTime":"0","endTime":"0","summary":"全球生物技术巨头CSL有限公司近日宣布，公司已启动与相关药品监管部门的密切沟通，共同探讨保障基因疗法Hemgenix长期稳定供应的战略方案。这一举措旨在应对潜在供应链挑战，确保这款突破性血友病B治疗药物能够持续满足全球患者的临床需求。通过建立多方协作机制，CSL将优化从原料采购到成品配送的全链条管理。此次战略合作凸显了CSL对患者用药可及性的长期承诺。CSL将通过技术创新与监管协作的双重路径，持续推动罕见病治疗领域的进步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7508","CSL.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"1138284712","title":"CSL Seqirus將攜手長期合作伙伴Sinergium Biotech 供應差異化流感疫苗組合","url":"https://stock-news.laohu8.com/highlight/detail?id=1138284712","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138284712?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 23:02","pubTimestamp":1773154962,"startTime":"0","endTime":"0","summary":"CSL有限公司旗下业务单元CSL Seqirus宣布，将与其长期合作伙伴Sinergium Biotech合作，共同供应其差异化的流感疫苗产品组合。此次合作旨在进一步拓展相关市场的疫苗可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7511","BK7508","BK7067","CSL.AU"],"gpt_icon":0},{"id":"1171042919","title":"世衞組織若宣佈流感大流行 CSL旗下Seqirus將為加拿大提供佐劑化細胞培養疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=1171042919","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171042919?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 21:05","pubTimestamp":1772715958,"startTime":"0","endTime":"0","summary":"如果世界卫生组织正式宣布进入流感大流行状态，CSL LIMITED（CSL.AU）旗下疫苗业务部门Seqirus已准备就绪，将向加拿大供应先进的佐剂化细胞培养流感疫苗。\n这种基于细胞培养技术生产的疫苗，相较于传统鸡胚培养方式，具有生产周期更短、应对病毒变异更灵活的优势。结合佐剂技术后，能有效增强免疫反应，在疫苗抗原用量相同的情况下可保护更多人群。\n该合作协议体现了加拿大政府对公共卫生应急能力的前瞻性布局，也展示了CSL集团在生物制药领域的技术储备与全球协作能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7501","BK7508","CSL.AU","BK7067"],"gpt_icon":0},{"id":"2612447563","title":"禮來加入IL‑6競爭，從CSL獲得clazakizumab部分權益","url":"https://stock-news.laohu8.com/highlight/detail?id=2612447563","media":"Minhua笔记","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612447563?lang=zh_tw&edition=fundamental","pubTime":"2026-02-18 17:07","pubTimestamp":1771405673,"startTime":"0","endTime":"0","summary":"2月17日，礼来宣布，与澳大利亚制药公司 CSL 达成许可协议，获得其 IL6 抑制剂 clazakizumab 的部分权益。目前尚不清楚礼来将 clazakizumab 用于哪些适应症。尽管该项目似乎契合礼来在心代谢领域的布局，但 CSL 将保留该抗体在终末期肾病患者中预防心血管事件的独家权益。根据协议，CSL 将获得 1 亿美元的首付款，并有资格获得未披露的临床、监管及商业里程碑付款，以及后续销售分成。CSL 于 2020 年通过收购 Vitaeris 获得 clazakizumab，而 Vitaeris 则在 2016 年从 Alder BioPharmaceuticals 引进该项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218174029a4afe813&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218174029a4afe813&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B1BXHZ80.USD","LU2168564222.USD","LU0256863902.USD","LU2552382058.USD","IE00B775H168.HKD","LU1804176565.USD","LU1917777945.USD","LU2237443978.SGD","CSL.AU","BK4581","LU0823416689.USD","LU2471134879.HKD","LU2108987350.USD","LU1366192091.USD","LU1267930730.SGD","LU0823434583.USD","LU2602419157.SGD","LU0943347566.SGD","LU2271345857.HKD","LU1868836914.USD","LU0006306889.USD","LU2471134523.USD","LU0889565916.HKD","BK4588","LU0198837287.USD","LU2089984988.USD","LU0786609619.USD","LU2111349929.HKD","LU1712237335.SGD","LU2471134952.CNY","LU1127390331.HKD","SG9999001176.USD","BK4086","LU2237443382.USD","IE0005OL40V9.USD","LU0354030438.USD","LU1169589451.USD","LU0203201768.USD","IE0004445239.USD","IE00BJJMRX11.SGD","IE00B4JS1V06.HKD","LU1023059063.AUD","IE00BKPKM429.USD","LU0109394709.USD","IE00BK4W5L77.USD","LU2112291526.USD","SGXZ23171101.USD","BK4516","LU2089284900.SGD","LU2468319806.SGD","LU2552382132.HKD","LU0964807845.USD","LU1983299246.USD","LU2236285917.USD","LU2471134796.USD","LU2237443622.USD","LU0289739699.SGD","LU2750360997.AUD","LU1064131342.USD","LU2237443549.SGD","LU2023250330.USD","LU2361044865.SGD","LU2746668974.SGD","LU2896262040.SGD","LU0417517546.SGD","LU0122379950.USD","LU0210536198.USD","LU0109391861.USD","SGXZ51526630.SGD","IE00BK4W5M84.HKD","LU0316494557.USD","LU0471298777.SGD","LU2360106947.USD","LU2264538146.SGD","SG9999018865.SGD","LLY","SG9999014898.SGD","LU0058720904.USD","IE00BJLML261.HKD","LU0820561909.HKD","LU1720051108.HKD","BK4533","SG9999014880.SGD","LU0323591593.USD","LU0882574139.USD","LU0158827948.USD","LU2087625088.SGD","LU0787776722.HKD","LU1629891620.HKD","LU2106854487.HKD","LU2491050154.USD","SG9999015986.USD","LU2265009873.SGD","LU0353189763.USD","IE00BFTCPJ56.SGD","SG9999014914.USD","LU1069344957.HKD","LU2417539215.USD","ELIS","LU1323610961.USD","LU2237438978.USD","SG9999015978.USD","LU0708995401.HKD","LU2237443465.HKD","LU2168564149.EUR","GB00BDT5M118.USD","SGXZ57979304.SGD","IE00BFSS7M15.SGD","IE00B2B36J28.USD","LU0061475181.USD","LU1623119135.USD","LU0266013472.USD","LU2756315318.SGD","BK4007","LU0823434740.USD","SG9999004303.SGD","LU2211815571.USD","LU2361044949.HKD","SG9999015945.SGD","LU2324357040.USD","LU2461242641.AUD","SGXZ99366536.SGD","LU1551013425.SGD","LU1035775433.USD","LU0320765059.SGD","LU0234572021.USD","LU1145028129.USD","IE00B1XK9C88.USD","IE00BJJMRZ35.SGD","LU1232071149.USD","SG9999014906.USD","LU1988902786.USD","LU0471298694.HKD","LU1061106388.HKD","IE00BJJMRY28.SGD","LU0096364046.USD","LU1057294990.SGD","LU1974910355.USD","LU1169590202.USD","SGXZ81514606.USD","LU2023251221.USD","SG9999017495.SGD","LU2462157665.USD","LU2491049909.HKD","IE0009355771.USD","LU1291159041.SGD","LU0456855351.SGD","LU2750360641.GBP","LU0466842654.USD","LU0256863811.USD","LU2168564065.EUR","LU0820561818.USD","LU1720051017.SGD","IE00BFSS8Q28.SGD","LU1868836591.USD","IE00B4R5TH58.HKD","LU2089283258.USD","LU2237443895.HKD","SG9999013999.USD","SGXZ31699556.SGD","IE0004445015.USD","LU0114720955.EUR","LU0882574055.USD","SG9999018857.SGD","LU0158827781.USD","LU2168563687.JPY","LU0353189680.USD","LLYX","LU0094547139.USD","LU1868836757.USD","LU0097036916.USD","LU0079474960.USD","LU1548497426.USD","LU1814569148.SGD","ELIL","LU0106261372.USD","SG9999015952.SGD","LU0689472784.USD","IE00BWXC8680.SGD","LU2456880835.USD","LU0640476718.USD","LU0728928796.USD","LU1551013342.USD","LU0672654240.SGD","LU1868837300.USD","LU0683600562.USD","IE00BN29S564.USD","LU1093756168.USD","LU1868837136.USD","BK4534","IE00BKDWB100.SGD","LU2213496289.HKD","LU2357305700.SGD","BK4599","LU0432979614.USD","IE0002141913.USD","LU2552382215.SGD","LU2028103732.USD","LU0320765992.SGD","LU1093756325.SGD","LU2756315664.SGD","LU0354030511.USD","IE00BJT1NW94.SGD","LU1989771016.USD","BK4585","LU2491050071.SGD","LU2063271972.USD","SG9999001176.SGD","LU2361045086.USD","LU0203202063.USD","LU0225283273.USD","LU2168564495.EUR","LU2746668461.USD","LU0238689110.USD","LU1280957306.USD","LU0820562030.AUD","IE00B7KXQ091.USD","LU0385154629.USD","LU2023250504.SGD","LLYZ"],"gpt_icon":1},{"id":"2612475639","title":"1億美元首付款！禮來引進一款IL-6單抗","url":"https://stock-news.laohu8.com/highlight/detail?id=2612475639","media":"Medaverse","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612475639?lang=zh_tw&edition=fundamental","pubTime":"2026-02-18 10:06","pubTimestamp":1771380360,"startTime":"0","endTime":"0","summary":"2月18日，CSL Limited宣布已与礼来公司签订了一项独家许可协议，授予其开发和商业化抗白细胞介素-6单克隆抗体clazakizumab的某些权利。clazakizumab由Vitaeris公司开发，并于2020年被CSL收购，是一种靶向IL-6的单克隆抗体，IL-6是一种与多种疾病发病机制有关的细胞因子。IL-6的过量产生与慢性炎症有关，并在一系列医疗条件下被观察到。CSL将获得1亿美元的预付款，并有资格获得潜在的临床、监管和商业里程碑付款，以及全球净销售额的特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218102000a705da54&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218102000a705da54&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2211815571.USD","LU2237443622.USD","LU2471134952.CNY","LU1629891620.HKD","LU2456880835.USD","LU2168563687.JPY","SG9999014898.SGD","LU2491050071.SGD","LU0353189680.USD","LU2746668974.SGD","LU2089283258.USD","LU2237443895.HKD","LU0096364046.USD","LU0210536198.USD","LU2237443465.HKD","LU1023059063.AUD","LU2471134879.HKD","LU2168564222.USD","LU2111349929.HKD","LU1035775433.USD","LU0708995401.HKD","LU2552382058.USD","LU2236285917.USD","LU2471134796.USD","LU0882574139.USD","LU0109391861.USD","LU2602419157.SGD","IE0002141913.USD","LU0266013472.USD","IE00BK4W5M84.HKD","BK4516","LU0238689110.USD","LU0823434583.USD","LU2023250504.SGD","LU2237443382.USD","CSL.AU","IE00BJJMRY28.SGD","LU1057294990.SGD","LU2106854487.HKD","LU1291159041.SGD","LU2417539215.USD","LU0256863902.USD","LU2461242641.AUD","SG9999014880.SGD","IE00BWXC8680.SGD","LU2471134523.USD","BK4534","LU0820561909.HKD","SG9999017495.SGD","IE00B775H168.HKD","LU0289739699.SGD","LU0058720904.USD","IE0009355771.USD","LU0203202063.USD","SG9999014906.USD","LU0316494557.USD","IE00B1XK9C88.USD","SG9999001176.SGD","LU2237443549.SGD","LU0964807845.USD","LU0683600562.USD","LU0889565916.HKD","IE00BN29S564.USD","LU0114720955.EUR","LU0823416689.USD","LU1127390331.HKD","LU0256863811.USD","LU0109394709.USD","LU2023251221.USD","LU0943347566.SGD","BK4581","LU1917777945.USD","LU1145028129.USD","LU2750360997.AUD","LU0198837287.USD","LU2746668461.USD","LU0640476718.USD","SG9999015978.USD","LU2168564065.EUR","SGXZ81514606.USD","LU0672654240.SGD","IE00BK4W5L77.USD","GB00BDT5M118.USD","SG9999015986.USD","LU0122379950.USD","LU0820562030.AUD","BK4599","IE00B2B36J28.USD","LU1366192091.USD","LU2237438978.USD","LU2756315664.SGD","LU1868837136.USD","LU1720051108.HKD","SGXZ51526630.SGD","SG9999014914.USD","BK4533","LU0786609619.USD","LU2896262040.SGD","LU1814569148.SGD","LU2360106947.USD","SG9999001176.USD","IE00BJJMRX11.SGD","LU0158827948.USD","LU1548497426.USD","IE0004445239.USD","LU1069344957.HKD","LU0097036916.USD","LU1868837300.USD","SG9999015952.SGD","LU2264538146.SGD","LU0882574055.USD","LU1551013342.USD","LU2468319806.SGD","LLY","LU0006306889.USD","LU1988902786.USD","LU0787776722.HKD","LU0106261372.USD","IE0004445015.USD","IE00BJJMRZ35.SGD","LU2361044865.SGD","LU2491050154.USD","IE00BKDWB100.SGD","LU0061475181.USD","SGXZ57979304.SGD","LU2361045086.USD","LU2462157665.USD","ELIL","LU1868836757.USD","LU1989771016.USD","LU0471298777.SGD","IE00BFTCPJ56.SGD","LLYX","LU0432979614.USD","LU2265009873.SGD","LU0456855351.SGD","LU1983299246.USD","LU0158827781.USD","IE00B4JS1V06.HKD","LU0417517546.SGD","LU2112291526.USD","LU0385154629.USD","LU2087625088.SGD","LU0094547139.USD","LU1093756168.USD","IE00B7KXQ091.USD","LU2089984988.USD","LU0354030511.USD","LU2552382132.HKD","BK4007","LU0820561818.USD","LU1232071149.USD","LU0471298694.HKD","LU0225283273.USD","LU1093756325.SGD","LU1720051017.SGD","LU2213496289.HKD","SGXZ31699556.SGD","LU1551013425.SGD","LU1064131342.USD","LU1267930730.SGD","LU0354030438.USD","LU2063271972.USD","LU0823434740.USD","IE00BJLML261.HKD","LU1868836914.USD","LU0320765992.SGD","BK4585","LU2028103732.USD","IE00B1BXHZ80.USD","ELIS","LU1623119135.USD","SG9999018857.SGD","IE0005OL40V9.USD","LU1804176565.USD","LU1974910355.USD","LLYZ","LU0353189763.USD","IE00BFSS7M15.SGD","BK4588","LU1712237335.SGD","IE00B4R5TH58.HKD","LU2168564149.EUR","IE00BKPKM429.USD","LU2491049909.HKD","LU2324357040.USD","SG9999013999.USD","LU0320765059.SGD","LU2756315318.SGD","LU0203201768.USD","LU2271345857.HKD","LU2552382215.SGD","LU2357305700.SGD","SGXZ99366536.SGD","LU2750360641.GBP","LU2237443978.SGD","LU0466842654.USD","IE00BFSS8Q28.SGD","LU0234572021.USD","LU1323610961.USD","LU0323591593.USD","IE00BJT1NW94.SGD","LU2168564495.EUR","LU2108987350.USD","SG9999015945.SGD","SG9999018865.SGD","LU1061106388.HKD","LU1868836591.USD","LU2361044949.HKD","LU1280957306.USD","LU0079474960.USD","LU0689472784.USD","LU2023250330.USD","LU2089284900.SGD"],"gpt_icon":1},{"id":"2612129491","title":"BUZZ-澳大利亞 CSL 公司與禮來公司簽署許可協議後恢復元氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2612129491","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612129491?lang=zh_tw&edition=fundamental","pubTime":"2026-02-18 08:32","pubTimestamp":1771374777,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nL4S3ZE01B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0471298694.HKD","BK4516","LU2361044949.HKD","SG9999015945.SGD","ELIL","LU2108987350.USD","BK4599","LU0466842654.USD","LU1868836591.USD","IE0004445015.USD","LU1804176565.USD","LU2168564495.EUR","LU1629891620.HKD","LU1323610961.USD","LU1989771016.USD","LU2168564149.EUR","LU1814569148.SGD","LU1720051017.SGD","IE00B4JS1V06.HKD","IE0005OL40V9.USD","LU2063271972.USD","LU0471298777.SGD","BK4585","LU0353189763.USD","IE00BJJMRX11.SGD","LU1093756168.USD","LU1127390331.HKD","SG9999014880.SGD","LU2756315664.SGD","LU0820562030.AUD","SG9999014898.SGD","SG9999014914.USD","LU0198837287.USD","LU2491050071.SGD","LU2237443622.USD","LU0106261372.USD","SGXZ51526630.SGD","LU1917777945.USD","LU0234572021.USD","SG9999001176.SGD","SG9999015986.USD","LU0320765059.SGD","LU1868836914.USD","IE00B775H168.HKD","IE00B1XK9C88.USD","LU0323591593.USD","LU0094547139.USD","LU0238689110.USD","SGXZ81514606.USD","LU2111349929.HKD","LU1551013342.USD","LU2237443895.HKD","LU1974910355.USD","LU2237443382.USD","LU2237443465.HKD","SG9999015978.USD","LU1064131342.USD","LLYX","IE00BWXC8680.SGD","LU0353189680.USD","IE00BFSS8Q28.SGD","LU0158827948.USD","LU1720051108.HKD","IE00BKDWB100.SGD","LU0823434740.USD","LU2023251221.USD","LU2237438978.USD","LU0158827781.USD","GB00BDT5M118.USD","LU2023250330.USD","LU2456880835.USD","SGXZ31699556.SGD","SG9999014906.USD","LU2168564065.EUR","LU1280957306.USD","IE00B2B36J28.USD","LU2023250504.SGD","LU0385154629.USD","LU2746668461.USD","IE0004445239.USD","LU2237443978.SGD","SG9999018857.SGD","LU2602419157.SGD","IE00BJT1NW94.SGD","IE0009355771.USD","LU2089984988.USD","LU2896262040.SGD","SG9999017495.SGD","LU0109391861.USD","LU0882574055.USD","IE00B7KXQ091.USD","LU2746668974.SGD","IE0002141913.USD","LU0061475181.USD","LU0823416689.USD","LU1035775433.USD","LU1548497426.USD","LU0823434583.USD","LU0354030511.USD","LU2361044865.SGD","LU0316494557.USD","LU0096364046.USD","LU0889565916.HKD","LU2213496289.HKD","SG9999013999.USD","SG9999018865.SGD","LU0210536198.USD","LU0006306889.USD","IE00BFTCPJ56.SGD","BK4588","LU0256863902.USD","LU2756315318.SGD","BK4534","BK7508","LU0079474960.USD","LU0203201768.USD","LU1868836757.USD","LU2106854487.HKD","IE00BJJMRZ35.SGD","LU0058720904.USD","LU0820561909.HKD","LU2028103732.USD","IE00BJJMRY28.SGD","LU2168563687.JPY","LU2471134523.USD","LU2360106947.USD","IE00BKPKM429.USD","SG9999015952.SGD","LU2468319806.SGD","BK7511","LLYZ","LU0354030438.USD","LU2087625088.SGD","LU1366192091.USD","IE00BK4W5L77.USD","LU1988902786.USD","IE00BFSS7M15.SGD","LU0787776722.HKD","BK4581","LU1023059063.AUD","LU2168564222.USD","LU2237443549.SGD","LU0820561818.USD","LU1623119135.USD","LU0672654240.SGD","LU0640476718.USD","LU1868837300.USD","LU2462157665.USD","LU1057294990.SGD","LU2324357040.USD","LU2211815571.USD","LU1983299246.USD","LU0456855351.SGD","LU2357305700.SGD","LU2461242641.AUD","IE00B1BXHZ80.USD","LU2750360641.GBP","LU1061106388.HKD","IE00BK4W5M84.HKD","LU0289739699.SGD","LU0097036916.USD","LU0432979614.USD","LU2112291526.USD","SG9999001176.USD","LU0882574139.USD","LU2491049909.HKD","LU0109394709.USD","LU1551013425.SGD","LU2089283258.USD","LU0225283273.USD","CSL.AU","LU0683600562.USD","LU0256863811.USD","BK7067","IE00BN29S564.USD","LU0320765992.SGD","LU0266013472.USD","LU2552382132.HKD","LU1069344957.HKD","IE00B4R5TH58.HKD","LU2361045086.USD","LU2236285917.USD","LU2471134796.USD","LU0786609619.USD","LU2089284900.SGD","LU0417517546.SGD","LU1093756325.SGD","SGXZ57979304.SGD","LU2471134952.CNY","LU2552382215.SGD","LU2417539215.USD","BK4007","BK4533","LU0122379950.USD","LU2265009873.SGD","BK7501","LU1145028129.USD","LU2552382058.USD","SGXZ99366536.SGD","LU2271345857.HKD","LU0943347566.SGD","LU0689472784.USD","LLY","LU0708995401.HKD","LU1291159041.SGD","IE00BJLML261.HKD","LU1267930730.SGD","LU2750360997.AUD","ELIS","LU1712237335.SGD","LU1232071149.USD","LU2264538146.SGD","LU2471134879.HKD","LU2491050154.USD","LU0203202063.USD","LU0964807845.USD","LU0114720955.EUR","LU1868837136.USD"],"gpt_icon":1},{"id":"2612549899","title":"更正-CSL 與禮來簽署克拉唑珠單抗許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2612549899","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612549899?lang=zh_tw&edition=fundamental","pubTime":"2026-02-18 05:24","pubTimestamp":1771363491,"startTime":"0","endTime":"0","summary":"更正-CSL 与礼来签署克拉唑珠单抗许可协议删除标题中有关肾病治疗协议的错误提法路透2月18日 - 澳大利亚CSLCSL.AX公司周三表示，它已与礼来公司LLLY.N签订了一项独家许可协议，授予该公司开发和商业化clazakizumab的某些权利，clazakizumab是一种旨在预防终末期肾病患者心脏相关疾病和死亡的抗体。 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"fbdc548d5c5e0ad4bd6dc716b0cc58c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nL4T3ZD1PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2265009873.SGD","IE00BFSS7M15.SGD","LU1988902786.USD","LU2552382215.SGD","SG9999017495.SGD","LU2417539215.USD","CSL.AU","LU1064131342.USD","IE00B775H168.HKD","LU1069344957.HKD","LU0882574139.USD","IE0002141913.USD","LLYZ","LU0058720904.USD","IE00B1XK9C88.USD","LU1868837300.USD","LU0079474960.USD","IE0004445239.USD","LU0823434740.USD","IE0009355771.USD","LU0882574055.USD","LU0786609619.USD","LU2357305700.SGD","ELIL","IE00B4JS1V06.HKD","LU2106854487.HKD","LU2746668461.USD","SG9999014898.SGD","LU0238689110.USD","LU0820561818.USD","LU1983299246.USD","LU1804176565.USD","BK7501","LU2089283258.USD","ELIS","IE00B1BXHZ80.USD","LU0106261372.USD","SG9999015945.SGD","LU1868836914.USD","SG9999014880.SGD","LLY","LU0683600562.USD","LU2750360641.GBP","SG9999013999.USD","LU1720051108.HKD","LU2168564495.EUR","LU0689472784.USD","LU0787776722.HKD","LLYX","SG9999018857.SGD"],"gpt_icon":0},{"id":"1120730244","title":"CSL有限公司簽署獨家許可協議 獲Clazakizumab開發及商業化特定權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1120730244","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120730244?lang=zh_tw&edition=fundamental","pubTime":"2026-02-18 05:14","pubTimestamp":1771362894,"startTime":"0","endTime":"0","summary":"CSL有限公司宣布达成一项独家授权协议，获得针对Clazakizumab的特定开发及商业化权利。该协议进一步拓展了公司在创新疗法领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"fbdc548d5c5e0ad4bd6dc716b0cc58c3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7511","BK7067","CSL.AU"],"gpt_icon":0},{"id":"2610095320","title":"全球市場-美國就業數據好於預期，股市和美元跳漲；人工智能隱憂未消","url":"https://stock-news.laohu8.com/highlight/detail?id=2610095320","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610095320?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 22:05","pubTimestamp":1770818719,"startTime":"0","endTime":"0","summary":"全球市场-美国就业数据好于预期，股市和美元跳涨；人工智能隐忧未消全程更新美国经济新增 13 万个就业岗位，超出预期人工智能担忧影响欧洲资产管理公司，STOXX 600 指数仍创历史新高高市赢得大选后日圆走强，无视刺激政策担忧。路透伦敦2月11日 - 美国股市期货和美元周三跳涨，此前数据显示，美国经济在1月份创造的就业岗位 远超预期，这可能使美联储今年继续降息变得更加困难。欧洲基准STOXX 600指数.STOXX上涨0.3%，创下历史新高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"578019e225999d0cd31d9b62b850b5ba","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4S3Z71CI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7508","BK7501","BK7511","BK7067"],"gpt_icon":0},{"id":"2610493111","title":"全球市場-對人工智能的擔憂加劇，股市暫停喘息；日圓大幅走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2610493111","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610493111?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 19:47","pubTimestamp":1770810476,"startTime":"0","endTime":"0","summary":"全球市场-对人工智能的担忧加剧，股市暂停喘息；日圆大幅走高更新价格，添加分析师评论欧洲股市持稳，美国期货上涨自日本大选以来，日圆对美元汇率上涨 2.5%零售销售疲软，美国就业数据受市场关注Harry Robertson. 路透伦敦2月11日 - 周三，欧洲股市变化不大，因为对人工智能干扰的担忧持续存在，而标普500指数期货走高，因为投资者在等待当天晚些时候的美国就业数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4T3Z70YX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7508","BK7501","BK7511","BK7067"],"gpt_icon":0},{"id":"2610883799","title":"全球市場-股市喘息，日圓飆升","url":"https://stock-news.laohu8.com/highlight/detail?id=2610883799","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610883799?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 14:03","pubTimestamp":1770789804,"startTime":"0","endTime":"0","summary":"全球市场-股市喘息，日圆飙升自日本大选以来，日圆对美元汇率上涨 2.5%CBA上涨；CSL跳水，澳股业绩季拉开帷幕标普500指数期货持稳；等待美国就业数据亚洲午后更新Tom Westbrook. 路透新加坡2月11日 - 周三，在美国零售销售数据不及预期之后，债券上涨，股市反弹放缓，而日圆涨势延续，可能开始预示著日本大选以来投资者思维的转变。通常情况下，股市上涨时日圆就会下跌，最近几个交易日，日本股市因预期政府会支持消费者而飙升至历史最高点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4T3Z70CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CSL.AU","BK7067","BK7501","BK7135","BK7511","CBA.AU"],"gpt_icon":0},{"id":"1128197629","title":"異動解讀 | 鐵劑仿製藥競爭持續施壓，CSL LIMITED盤中大跌9.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1128197629","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128197629?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 07:03","pubTimestamp":1770764591,"startTime":"0","endTime":"0","summary":"CSL LIMITED (CSL.AU) 今日盘中股价大跌9.15%，引发了市场的高度关注。消息面上，CSL有限公司旗下业务板块CSL Vifor的财务表现，预计将持续受到铁剂产品领域仿制药竞争的负面冲击。这一竞争态势可能对相关产品的市场份额和盈利能力构成长期压力，导致投资者信心受挫，从而引发股价大幅下跌。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CSL.AU"],"gpt_icon":0},{"id":"1166848952","title":"CSL有限公司：CSL Vifor業績將因鐵劑產品仿製藥競爭持續承壓","url":"https://stock-news.laohu8.com/highlight/detail?id=1166848952","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166848952?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 04:44","pubTimestamp":1770756259,"startTime":"0","endTime":"0","summary":"CSL有限公司旗下业务板块CSL Vifor的财务表现，预计将持续受到铁剂产品领域仿制药竞争的负面冲击。这一竞争态势可能对相关产品的市场份额和盈利能力构成长期压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","CSL.AU","BK7508","BK7067","BK7511"],"gpt_icon":0},{"id":"1190947418","title":"CSL有限公司：免疫球蛋白、白蛋白及新品上市將驅動CSL Behring下半年業績增長","url":"https://stock-news.laohu8.com/highlight/detail?id=1190947418","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190947418?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 04:44","pubTimestamp":1770756257,"startTime":"0","endTime":"0","summary":"全球生物技术巨头CSL有限公司旗下核心业务单元CSL Behring预计，2023财年下半年业绩增长将主要受益于三大产品板块的强劲表现。免疫球蛋白产品线作为公司传统优势领域，将继续发挥市场领导作用。伴随全球范围内免疫缺陷疾病诊断率的提升及治疗需求的持续扩张，该业务板块有望维持稳定增长态势。值得注意的是，近期通过创新管线上市的新一代特药产品已展现出显著市场潜力。公司通过优化产品组合策略，正构建多层次、可持续的增长格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","BK7501","BK7067","CSL.AU"],"gpt_icon":0},{"id":"1195673475","title":"Memo Therapeutics將利用Dropzylla平台開發重組多克隆抗體 實現抗體庫克隆與表達","url":"https://stock-news.laohu8.com/highlight/detail?id=1195673475","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195673475?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 20:17","pubTimestamp":1770639465,"startTime":"0","endTime":"0","summary":"Memo Therapeutics AG宣布，公司将采用其专有的Dropzylla技术平台，开展重组多克隆免疫球蛋白G（IgG）的研发工作。该平台具备克隆抗体库及表达抗体的核心功能，有望推动新一代抗体疗法的创新突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7067","BK7508","CSL.AU","BK7501"],"gpt_icon":0},{"id":"1179756861","title":"Memo Therapeutics Ag與CSL達成合作與期權協議 共同開發重組多克隆IgG技術","url":"https://stock-news.laohu8.com/highlight/detail?id=1179756861","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179756861?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 20:13","pubTimestamp":1770639222,"startTime":"0","endTime":"0","summary":"Memo Therapeutics Ag近日宣布与CSL LIMITED签署了一项合作与期权协议，双方将携手推进重组多克隆IgG技术的研发进程。该协议标志着两家公司在生物医药领域的深度合作正式启动，旨在加速创新疗法的开发与应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU","BK7501","BK7511","BK7067","BK7508"],"gpt_icon":0},{"id":"2605669452","title":"焦點-美國衞生部長肯尼迪的言論成為現實，疫苗生產商倍感寒意","url":"https://stock-news.laohu8.com/highlight/detail?id=2605669452","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605669452?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 14:02","pubTimestamp":1769061735,"startTime":"0","endTime":"0","summary":"焦点-美国卫生部长肯尼迪的言论成为现实，疫苗生产商倍感寒意肯尼迪的疫苗政策转变引发业界不满专家认为疫苗接种率下降与美国的言论有关以疫苗为重点的生物技术公司面临估值压力Bhanvi Satija. 路透伦敦1月22日 - 美国卫生部长小罗伯特-肯尼迪（Robert F. Kennedy Jr.美国总统特朗普（Donald Trump）的政府 (link) 在过去一年里颠覆了疫苗接种建议，美国上个月终止了长期以来要求所有儿童接种疫苗预防流感、甲型肝炎和其他疾病的指导意见。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nL4T3YN0CV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1929549753.HKD","SG9999015341.SGD","IE000M9KFDE8.USD","LU0070302665.USD","IE00B3T34201.USD","IE0002141913.USD","LU1116320901.HKD","IE00BQJZX424.USD","IE00B19Z3581.USD","CSL.AU","LU0971552673.USD","IE00B19Z3B42.SGD","LU2324357040.USD","BK7508","LU0477156953.USD","LU0203347892.USD","BK5011","LU1400636491.USD","IE00BJJMRZ35.SGD","BK4535","LU0130517989.USD","LU1983299246.USD","LU2360032135.SGD","BK7067","SG9999001176.SGD","LU1093756168.USD","LU1934455863.HKD","LU0161305163.EUR","LU2125154935.USD","LU2112291526.USD","LU0965509010.AUD","LU0234572021.USD","LU0109981661.USD","LU1917777945.USD","LU1309081286.SGD","SG9999014559.SGD","LU1093756325.SGD","LU1934455277.USD","LU2125154778.USD","BK4581","LU0208291251.USD","LU1228905037.USD","BK4550","LU0098860793.USD","LU0122379950.USD","LU0868494617.USD","BK4568","BK4534","LU0266013472.USD","LU1061106388.HKD","LU1670756490.USD","LU0306807586.USD","BK4533","BK4547","IE00BN8TJ469.HKD","LU0106261372.USD","LU2361044949.HKD","SG9999015358.SGD","BK4551","LU1162221912.USD","SG9999003800.SGD","LU0238689110.USD","LU0575583348.USD","LU0306806265.USD","LU1934455194.USD","LU1098665638.USD","BK4516","LU1400636574.HKD","BK4139","IE00BLSP4452.SGD","BK4548","IE00B4R5TH58.HKD","LU1046248800.SGD","LU1894683348.USD","LU0225771236.USD","LU1989772840.SGD","LU2361044865.SGD","LU1883839398.USD","LU1699723380.USD","SG9999011175.SGD","LU0265550946.USD","IE00B2B36J28.USD","LU1941712264.USD","LU2089984988.USD","LU1481599808.USD","LU0861579265.USD","LU1400636657.SGD","LU1430594728.SGD","IE00BBT3K403.USD","LU1023059063.AUD","IE00BWDBJ516.SGD","LU1989771016.USD","SG9999014542.SGD","IE00BSNM7G36.USD","LU1202635105.USD","LU1974910355.USD","LU2361045086.USD","LU1037948897.HKD","LU1302929846.USD","BK7511","IE00BJT1NW94.SGD","BK4007","LU0130102774.USD","IE0034235071.USD","BK4585","LU1037948541.HKD","LU0170899867.USD","BK4501","SG9999014567.USD","BK7501","IE0002270589.USD","LU0648001328.SGD","SG9999014575.USD","IE00BLSP4239.USD","SG9999001176.USD","LU0965508806.USD","LU1585245621.USD","LU1064927863.SGD","LU1645745479.HKD","LU0058720904.USD","MRNA","LU0980610538.SGD","LU2468319806.SGD","LU0321505868.SGD","LU2023250843.SGD","LU0321505439.SGD","SGXZ57979304.SGD","LU0545562505.USD","LU0320765646.SGD","LU1066051225.USD","LU1069347547.HKD","LU1487256676.USD","LU0965509283.SGD","BK4532","BK4559","BK4588","LU0265550359.USD","LU1894683264.USD","GSK","BNTX","LU0211331839.USD","NVAX","LU0320765489.SGD","LU1989772923.USD","LU1116320737.USD","LU2023250504.SGD","LU2461242641.AUD","PFE","LU1035773651.USD","LU0006306889.USD","LU1066051498.USD","IE0009355771.USD","LU1941712348.USD","LU1035777561.USD","BK4599","LU1228905540.USD","LU2106854487.HKD","BK4592","LU1481600234.SGD","LU0225284248.USD","LU1291159041.SGD","LU0971552830.HKD","LU1201861249.SGD","LU1066051811.HKD","IE00BFTCPJ56.SGD","LU1066053197.SGD","IE00B1BXHZ80.USD","LU0985481810.HKD","LU0985320562.USD","LU1015430645.USD","LU0456855351.SGD","SG9999002224.SGD","LU0965509101.SGD","LU1571399168.USD","LU0289739699.SGD","MRK","LU1057294990.SGD","SG9999002232.USD","SG9999013999.USD","LU0203345920.USD","SG9999001440.SGD"],"gpt_icon":1},{"id":"1105461883","title":"異動解讀 | CSL LIMITED盤中大漲5.27%，子公司簽署重要備忘錄","url":"https://stock-news.laohu8.com/highlight/detail?id=1105461883","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105461883?lang=zh_tw&edition=fundamental","pubTime":"2025-10-30 13:56","pubTimestamp":1761803788,"startTime":"0","endTime":"0","summary":"周四盘中，澳大利亚生物制药巨头CSL LIMITED股价大涨5.27%，引发市场广泛关注。这一显著涨幅或与公司旗下子公司最新业务进展密切相关。据悉，CSL LIMITED的疫苗部门CSL Seqirus近期与疫苗工业公司及卫生部签署了一份重要的谅解备忘录。分析人士认为，这份谅解备忘录的签署显示了CSL LIMITED在疫苗业务上的持续创新和扩张战略，可能会为公司带来新的收入增长点。投资者对这一发展前景表示乐观，推动了CSL LIMITED股价的强劲上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CSL.AU"],"gpt_icon":0},{"id":"1185215746","title":"CSL LIMITED - CSL Seqirus與疫苗工業公司與衞生部簽署重要諒解備忘錄","url":"https://stock-news.laohu8.com/highlight/detail?id=1185215746","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185215746?lang=zh_tw&edition=fundamental","pubTime":"2025-10-30 13:55","pubTimestamp":1761803711,"startTime":"0","endTime":"0","summary":"CSL LIMITED - CSL Seqirus与疫苗工业公司与卫生部签署重要谅解备忘录","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK7508","CSL.AU","BK7511"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":25,"code":"91000000","status":"200"}]}}